- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Ionis gets a milestone approval; Another top FDA official to step down | ||
| Fr | Novo's next-gen obesity drug misses expectations in closely watched trial | ||
| Do | Roche sticks with Parkinson's drug despite second study failure | ||
| Do | A venture firm breathes new life into an old NGM drug | ||
| Do | Regeneron says study data support big bet on new blood thinners | ||
| Do | Vertex 'ends the year in pain' as latest non-opioid drug data disappoint | ||
| Do | Novartis shutters MorphoSys sites, lays off staff | ||
| Do | Zepbound, Mounjaro shortages are resolved, FDA confirms | ||
| Do | Ottimo raises $140M to compete in chase for new type of cancer drug | ||
| Mi | Merck moves into obesity with deal for Hansoh's GLP-1 pill | ||
| Mi | Tessera gets sickle cell funding; Corvus shares slide on eczema data | ||
| Mi | Stopgap funding bill includes PBM reforms, preserves telehealth flexibility | ||
| Mi | A Vertex partner - and potential rival - secures $100M to develop non-opioid pain drugs | ||
| Di | Namandjé Bumpus, FDA's No. 2 official, to depart agency at end of year | ||
| Di | Merck targets 2025 RSV season with antibody now under FDA review | ||
| Di | Pfizer predicts stability, to Wall Street's relief | ||
| Di | Sanofi, Teva say study results show gut disease drug could be 'best in class' | ||
| Mo | Jazz to search for new chief as CEO plans retirement | ||
| Mo | Edgewise weighs fast approval path for muscular dystrophy drug | ||
| Mo | Novo builds up manufacturing; Pepgen Duchenne trial put on hold | ||
| Mo | Novo Holdings' purchase of Catalent set to close after regulators' green light | ||
| Mo | Could the gut microbiome hold the key to fighting cancer? | ||
| Mo | Are we overlooking something critical in cell and gene therapy research? | ||
| 13.12. | CMS says private Medicare plans can't automatically deny Biogen's ALS drug | ||
| 13.12. | FDA panel seeks more data on RSV vaccine safety in infants |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
